

February 27, 2025

Gov. Tim Walz  
75 Rev. Dr. Martin Luther King Jr. Blvd  
130 State Capitol  
St. Paul, MN 55155

Rep. Tim O'Driscoll, Chair  
Commerce Finance & Policy Comm.  
Centennial Office Bldg., 2nd Fl.  
St. Paul, MN 55155  
*rep.tim.odriscoll@house.mn.gov*

Sen. Matt D. Klein, Chair  
Commerce & Consumer Protection Comm.  
2105 Minnesota Senate Bldg.  
St. Paul, MN 55155  
*sen.matt.klein@mnsenate.gov*

Rep. Bernie Perryman, Vice Chair  
Commerce Finance & Policy Comm.  
Centennial Office Bldg., 2nd Fl.  
St. Paul, MN 55155  
*rep.bernie.perryman@house.mn.gov*

Sen. Gary H. Dahms, Ranking Member  
Commerce & Consumer Protection Comm.  
2219 Minnesota Senate Bldg.  
St. Paul, MN 55155  
*sen.gary.dahms@mnsenate.gov*

Rep. Kaohly Vang Her, DFL Lead  
Commerce Finance & Policy Comm.  
Centennial Office Bldg., 5th Fl.  
St. Paul, MN 55155  
*rep.kaohly.her@house.mn.gov*

## **RE: Annual Report Minnesota's Prescription Drug Affordability Board**

Dear Governor Walz, Senators, and Representatives:

I am writing as Chair of Minnesota's Prescription Drug Affordability Board. The Board was duly constituted by the appointment process described in Minnesota Statutes section 62J.87 and began meeting in March, 2024. Separately, I can report that the Prescription Drug Affordability Advisory Council, which was established in section 62J.88 and was created "to provide advice to the board on drug cost issues and to represent stakeholders' views," also began meeting in 2024. The Board's initial meetings in 2024 focused on organizational functions, hiring of the Board's executive director (which remains pending), review of data sources on drug pricing, study of the pharmaceutical supply chain, review of the Minnesota Department of Health's Drugs of Substantial Public Interest report released in June, and review of other reporting on pharmaceutical issues. In addition, the Board took public comment from interested stakeholders at each of its public meetings.

Minnesota Statutes section 62J.93 requires that on an annual basis "the board shall submit a report to the governor and legislature on general price trends for prescription drug products and the number of prescription

drug products that were subject to the board's cost review and analysis, including the result of any analysis as well as the number and disposition of appeals and judicial reviews.” The Board has not yet completed cost review and analysis of any prescription drug products, but it continues to work on these issues and will report on these important issues in the future.

Please contact me if you have any questions.

Sincerely,

**/s/ Tony Lourey**

TONY LOUREY

Chair

Prescription Drug Affordability Board

cc: Legislative Reference Library  
Chris Steller  
658 Cedar Street  
Centennial Office Bldg.  
St. Paul, MN 55155-1050

Email only: *reports@lrl.mn.gov* (Legislative Reference Library)  
*eamonn.g.schmitz@state.mn.us* (Office of Gov. Tim Walz & Lt. Gov. Peggy Flanagan)  
*bill.lunzer@mnsenate.gov* (Committee Administrator, Commerce and Cons. Prot. Committee)  
*jonathan.cotter@house.mn.gov* (Committee Administrator, Commerce Finance and Policy)  
*julia.dreier@state.mn.us* (Minnesota Department of Commerce)